The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
HudesG.R., NathanF.E., KhaterC.Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.Sem Oncol.1995; 22(supp 12): 41–5.
2.
HudesG.R., NathanF.E., KhaterC.Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer.J Clin Oncology.1997; 15: 3156–63.
3.
PetrylakD.P., MacarthurR., O'ConnorJ.Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.Sem Oncol.1999; 26(supp 17): 28–33.
4.
SinibaldiV.J., CarducciM., LauferM.Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.Sem Oncol.1999; 26(supp 17): 45–8.
5.
KellyW.K., CurleyT., SlovinS.Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.J Clin Oncol.2001; 19: 44–53.
6.
PientaK.J., SmithD.C.Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.Sem Oncol.1997; 24(supp 15): S15.72–S15.77.
7.
SmithD.C., EsperP., StrawdermanM.Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.J Clin Oncol.1999; 17: 1664–71.
8.
SavareseD., TaplinM., HalabiS.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B trial 9780.Sem Oncol.1999; 26(5 Suppl 17): 39–44.
9.
CohenM.R., SmetzerJ.Preparing for a damaging medication error.ISMP Medication Safety Alert!1999; 4: 14.
10.
CohenM.R., SmetzerJ.Preparing for a damaging medication error.ISMP Medication Safety Alert!2001; 6: 3.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
12.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
13.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM].Rockledge, PA: National Comprehensive Cancer Network; 2001.
14.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
15.
MorrowG.R., HickockJ.T., RosenthalS.N.Progress in reducing nausea and emesis: Comparisons of ondansetrion (Zofran), granisetron (Kytril), and tropesetron (Navoban).Cancer.1995; 76(3): 343–57.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
23.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
24.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36: S15–21.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
26.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
27.
Estramustine phosphate.In Door RT, Von Hoff DD (eds.): Cancer Chemotherapy Handbook.2nd ed.Norwalk, CT: Appleton & Lange; 1994, 443–6.
28.
VenookA.P., EgorinM.J., RosnerG.L.Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.J Clin Oncol.1998; 16(5): 1811–9.
